BR0112453A - Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de compasso - Google Patents

Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de compasso

Info

Publication number
BR0112453A
BR0112453A BR0112453-6A BR0112453A BR0112453A BR 0112453 A BR0112453 A BR 0112453A BR 0112453 A BR0112453 A BR 0112453A BR 0112453 A BR0112453 A BR 0112453A
Authority
BR
Brazil
Prior art keywords
psoriasis
bone
compound
sinus
compass
Prior art date
Application number
BR0112453-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Hector F Deluca
Connie M Smith
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BR0112453A publication Critical patent/BR0112453A/pt

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/2236—Equipment for loosening or ejecting castings from dies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22D—CASTING OF METALS; CASTING OF OTHER SUBSTANCES BY THE SAME PROCESSES OR DEVICES
    • B22D17/00—Pressure die casting or injection die casting, i.e. casting in which the metal is forced into a mould under high pressure
    • B22D17/20—Accessories: Details
    • B22D17/22—Dies; Die plates; Die supports; Cooling equipment for dies; Accessories for loosening and ejecting castings from dies
    • B22D17/24—Accessories for locating and holding cores or inserts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0112453-6A 2000-07-14 2001-07-10 Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de compasso BR0112453A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/616,778 US6306844B1 (en) 1997-03-17 2000-07-14 Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
PCT/US2001/021660 WO2002005824A1 (en) 2000-07-14 2001-07-10 USE OF 2α-METHYL-19-NOR-20(S)-1α,25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH

Publications (1)

Publication Number Publication Date
BR0112453A true BR0112453A (pt) 2003-08-19

Family

ID=24470903

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112453-6A BR0112453A (pt) 2000-07-14 2001-07-10 Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de compasso

Country Status (16)

Country Link
US (4) US6306844B1 (cg-RX-API-DMAC7.html)
EP (1) EP1305030B1 (cg-RX-API-DMAC7.html)
JP (1) JP4955895B2 (cg-RX-API-DMAC7.html)
KR (1) KR100572958B1 (cg-RX-API-DMAC7.html)
CN (1) CN1250225C (cg-RX-API-DMAC7.html)
AT (1) ATE359796T1 (cg-RX-API-DMAC7.html)
AU (2) AU7330301A (cg-RX-API-DMAC7.html)
BR (1) BR0112453A (cg-RX-API-DMAC7.html)
CA (1) CA2416187A1 (cg-RX-API-DMAC7.html)
DE (1) DE60127964T2 (cg-RX-API-DMAC7.html)
DK (1) DK1305030T3 (cg-RX-API-DMAC7.html)
ES (1) ES2286129T3 (cg-RX-API-DMAC7.html)
IL (2) IL153908A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03000405A (cg-RX-API-DMAC7.html)
NZ (1) NZ524018A (cg-RX-API-DMAC7.html)
WO (1) WO2002005824A1 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
AU2001278888B2 (en) * 2000-07-14 2005-04-07 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin D3 to increase bone strength
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US20030195175A1 (en) * 2002-03-25 2003-10-16 Deluca Hector F. Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
DE60310050T2 (de) 2002-03-29 2007-07-05 Wisconsin Alumni Research Foundation, Madison Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacalciferol
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
RU2317992C2 (ru) 2003-02-25 2008-02-27 Кей Эн Си Лэборэтериз Ко., Лтд. Новые промежуточные соединения для синтеза производных витамина d
CA2539361A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
US7214671B2 (en) * 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
NZ555278A (en) * 2004-11-22 2010-12-24 Wisconsin Alumni Res Found 17,20(e)-dehydro vitamin D analogs and their uses
US20100144671A1 (en) * 2005-03-04 2010-06-10 Women And Infants Hospital Of Ri, Inc. Compositions and Methods for Cancer Treatment
US7241909B2 (en) * 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US7803789B2 (en) * 2006-02-02 2010-09-28 Wisconsin Alumni Research Foundation Vitamin D analog—RAK, methods and uses thereof
AU2007234717B2 (en) * 2006-04-06 2012-04-19 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
MX2008012114A (es) * 2006-04-06 2009-03-06 Wisconsin Alumni Res Found Analogos 19-nor-vitamina d con anillo 1,2, o 3,2 heterociclico.
AU2007298673A1 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2- substituted-1alpha, 25-dihydroxy-19,26,27-trinor vitamin D analogs and uses thereof
AU2007349772A1 (en) * 2006-04-06 2008-10-23 Wisconsin Alumni Research Foundation 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof
EP2001841B1 (en) * 2006-04-06 2012-06-13 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
MX2008012674A (es) * 2006-04-10 2008-10-15 Wisconsin Alumni Res Found Compuestos de 1 a-hidroxi-2-(3'-hidroxipropiliden)-19-nor-vitamina d con una cadena lateral 1,1-dimetilpropilo.
EP2020989A2 (en) * 2006-05-15 2009-02-11 Wisconsin Allumni Research Foundation Pulmonary delivery of 1,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US8222236B2 (en) * 2008-07-10 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
WO2011017165A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
CA2777938C (en) * 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
ES2545403T3 (es) * 2010-03-23 2015-09-10 Wisconsin Alumni Research Foundation (20S)-2-metilen-19-nor-22-dimetil-1alfa,25-dihidroxivitamina D3 y (20R)-2-metilen-19-nor-22-dimetil-1alfa,25-hidroxivitamina D3
WO2011119622A1 (en) * 2010-03-23 2011-09-29 Wisconsin Alumni Research Foundation DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1α,25- DIHYDROXYVITAMIN D3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US20130295083A1 (en) * 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
RU2666995C2 (ru) 2012-06-29 2018-09-13 Висконсин Алюмни Рисерч Фаундейшн ПРИМЕНЕНИЕ 2-МЕТИЛЕН-19-НОР-(20S)-1α,25-ДИГИДРОКСИВИТАМИНА D3 ДЛЯ ЛЕЧЕНИЯ ВТОРИЧНОГО ГИПЕРПАРАТИРЕОЗА
US9539264B2 (en) 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
WO2017184262A1 (en) * 2016-04-18 2017-10-26 Wisconsin Alumni Research Foundation Use of 2amd and 2md to treat fibrosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0078704B1 (en) 1981-11-02 1987-04-29 Research Institute For Medicine And Chemistry Inc. Intermediates in the synthesis of vitamin d derivatives
US4666634A (en) 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
DK0474517T3 (da) 1990-09-07 1999-08-02 Wisconsin Alumni Res Found Hidtil ukendt anvendelse af 1alfa-hydroxyleret-19-nor-vitamin D-
US5086191A (en) 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5962707A (en) * 1998-08-18 1999-10-05 Wisconsin Alumni Research Foundation 19-nor-vitamin D3 compounds with calcemic activity

Also Published As

Publication number Publication date
EP1305030A1 (en) 2003-05-02
JP4955895B2 (ja) 2012-06-20
ATE359796T1 (de) 2007-05-15
CA2416187A1 (en) 2002-01-24
US20060003973A1 (en) 2006-01-05
EP1305030B1 (en) 2007-04-18
AU7330301A (en) 2002-01-30
CN1501803A (zh) 2004-06-02
DE60127964D1 (de) 2007-05-31
DK1305030T3 (da) 2007-09-17
IL153908A0 (en) 2003-07-31
IL153908A (en) 2009-08-03
JP2004509853A (ja) 2004-04-02
HK1066487A1 (en) 2005-03-24
AU2001273303B8 (en) 2006-03-09
AU2001273303B2 (en) 2006-02-02
US20040072804A1 (en) 2004-04-15
US20020151528A1 (en) 2002-10-17
KR20030016402A (ko) 2003-02-26
NZ524018A (en) 2006-06-30
US6306844B1 (en) 2001-10-23
WO2002005824A1 (en) 2002-01-24
US6939868B2 (en) 2005-09-06
MXPA03000405A (es) 2003-06-06
KR100572958B1 (ko) 2006-04-24
DE60127964T2 (de) 2008-01-17
CN1250225C (zh) 2006-04-12
ES2286129T3 (es) 2007-12-01

Similar Documents

Publication Publication Date Title
BR0112453A (pt) Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de compasso
BR0112454A (pt) Métodos de tratamento de doença metabólica do osso, psorìase, leucemia, câncer do cólon, do seio ou da próstata e de aumento da força de um osso e uso de composto
IL164688A0 (en) Pharmaceutical compositions containing 1?-hydroxy-2-methyl-19-nor-vitamin D3 compounds
CO5280047A1 (es) Compuestos de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
BR9808010B1 (pt) Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
GEP20063855B (en) Small organic molecule regulators of cell proliferation
IL138319A0 (en) MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
CO5190686A1 (es) Compuesto de indazol y composiciones farmaceuticas para la inhibicion de proteina kinasa
ECSP066335A (es) Compuestos de indazol 3,5-disustituidos, composiciones farmacéuticas y métodos para intervenir en o inhibir la proliferación celular
AR005987A1 (es) Terapia combinada para la osteoporosis
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
DOP2001000120A (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar e inhibir la proliferación celular
PA8493701A1 (es) Compuestos para tratar la obesidad
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
ATE556999T1 (de) 2-propyliden-19-nor-vitamin d verbindungen
ATE321856T1 (de) Humane rezeptortyrosinkinase
UY26877A1 (es) Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
DE60236411D1 (de) Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe
UY26651A1 (es) Terapia combinada para la osteoporosis
DOP2003000788A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso
UY26547A1 (es) Compuestos de amida y composiciones farmacéuticas para inhibir proteinquinasas, y su modo de empleo
UY26543A1 (es) Compuestos, composiciones farmacéuticas de indazol y métodos para mediar o inhibir la proliferación celular.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]